Format

Send to

Choose Destination
Trends Biotechnol. 2016 Feb;34(2):86-90. doi: 10.1016/j.tibtech.2015.12.002.

Providing Appropriate Risk Information on Genome Editing for Patients.

Author information

1
Office of Health and Safety, Hokkaido University, Sapporo Hokkaido, 060-0808, Japan.
2
Office of Health and Safety, Hokkaido University, Sapporo Hokkaido, 060-0808, Japan. Electronic address: tishii@general.hokudai.ac.jp.

Abstract

Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.

KEYWORDS:

CRISPR/Cas9; clinical application; genome editing; informed consent; off-target mutation; society

PMID:
26802361
DOI:
10.1016/j.tibtech.2015.12.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center